newsfilter
← Latest News
GlobeNewswire·

NGM Bio Provides Business Highlights and Reports Second Quarter 2022 Financial Results

--Initiated Phase 1/1b clinical trial of NGM438, a LAIR1 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) for the treatment of patients with advanced solid tumors-- --Initiated the Phase1b port